Litigation

Par Pharmaceutical, Inc. et al. v. Jazz Pharmaceuticals, Inc.

final written decision; claims unpatentable

IPR2015-00551

Auto-generating section 1 of 5: Case overview & background…

Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.

Court: Patent Trial and Appeal Board, U.S. Patent and Trademark Office
Filed: 2015-01-08
Terminated: 2016-07-27

Patents at issue (1)

Plaintiffs (2)

Defendants (1)

Δ Jazz Pharmaceuticals, Inc.

Summary

Par and Amneal petitioned for inter partes review of the '988 patent. The PTAB instituted the review and issued a final written decision on July 27, 2016 holding claims 1–15 of the '988 patent unpatentable as obvious over the Advisory Committee Art, with Korfhage as to claims 2 and 10.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

In the news

What the press has reported about this case, summarized with links to the source articles.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Record id: 8457988-ipr2015-00551 · edit in Admin

Further reading

Non-Practicing Entity (NPE) lawsuit defense: a defendant's playbook
Defending an NPE suit is different from defending a competitor's suit. The asymmetries cut both ways — and the right plays exploit the ones that favor the defendant.
How patent trolls operate (and why the business model works)
A junk patent generates settlement income exactly the same way as a strong one, because nobody pays $1M to test a $200k demand. The mechanics matter because the failure modes — what makes assertion campaigns expensive or risky for the troll — are exactly where defendants find leverage.
Most-litigated US patents: 12 patents that defined the patent troll era
If a demand letter lands on your desk citing one of these, you are not the first. The campaign playbook is on file. The defenses other defendants used are public record.
Patent trolls in 2025: the year in numbers
2025 was a banner year for patent trolls — and not by accident. Filings surged while the defendant's cheapest weapon, the PTAB, was quietly taken off the table. Here's what the reporting shows, and why the two are connected.
How to read a patent claim chart
The claim chart is where the plaintiff's case actually lives. The complaint is a pitch deck; the chart is the homework — and most patent troll homework doesn't survive a careful read.

All resources →